Ovarian Cancer Diagnostics & Therapeutics Market

Ovarian Cancer Diagnostics & Therapeutics Market by Modality (Therapeutics (Chemotherapy, Radiation Therapy, Immunotherapy, Hormonal Therapy, and Others), Diagnosis (Biopsy, Blood Tests, Ultrasound, PET, CT scan, and Others), Cancer Types (Ovarian Germ Cell Tumors, Epithelial Ovarian Tumors, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-3289
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 1
  • No. Of Pages: 213
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global ovarian cancer diagnostics & therapeutics market size is projected to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to changing lifestyle and cancer risk in the female population.

Breast and female reproductive part cancer affect about 3 million people worldwide each year. While high-income nations have made tremendous success in preventing cervical and ovarian cancer and controlling breast cancer, low- and middle-income countries account for approximately 80% of cancer fatalities (LMICs).

Ovarian Cancer Diagnostics & Therapeutics Market Key Takeaways

Ovarian cancer was the eighth most prevalent cancer in women and the 18th most common cancer in 2018, according to the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research. In 2018, over 300,000 new cases of ovarian cancer were recorded.

Ovarian cancer develops when cells in the ovaries increase uncontrolled, resulting in a mass of tissue known as a tumor. Researchers have made significant progress in understanding how specific mutations (changes) in DNA may cause cancer in normal cells.

Ovarian cancer risk rises with age, with the majority of occurrences occurring after menopause. Ovarian cancer affects around 8 out of every 10 women over the age of 50, however some uncommon kinds of ovarian cancer can strike younger people.

The growing necessity for early identification of ovarian cancer in order to reduce death rates is predicted to propel the ovarian cancer diagnostics market.

Various projects are being launched by governments across the world to educate people about ovarian cancer and the benefits of early detection. Additionally, increased spending and investment on ovarian cancer research efforts in order to develop efficient early detection tools would boost market.

Market Trends, Drivers, Restraints, and Opportunities

  • Rising elderly population is expected to boost the market during the forecast period.
  • Introduction of sophisticated equipment in diagnostic procedures is projected to drive the market in the coming years.
  • Increasing cases of ovarian cancer and growing awareness are anticipated to fuel the market.
  • Growing ovarian cancer research spending and effort in order to discover viable techniques are expected to boost the market in the coming years.
  • Rising consumption of birth control pills among females is estimated to fuel the market.
  • High treatment cost act as key challenge that can hamper the market growth.
  • Diagnostic procedures are only efficient in identifying the spread of ovarian cancer at advanced stages, due to the disease's inability to be detected early is expected to hamper the market.

Scope of the Report

The report on the global ovarian cancer diagnostics & therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Ovarian Cancer Diagnostics & Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Modality (Therapeutics (Chemotherapy, Radiation Therapy, Immunotherapy, Hormonal Therapy, and Others) and Diagnosis (Biopsy, Blood Tests, Ultrasound, PET, CT scan and Others), Cancer Types (Ovarian Germ Cell Tumors, Epithelial Ovarian Tumors, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Glaxosmithkline Plc.; Johnson and Johnson; Astrazeneca plc.; F. Hoffmann-La Roche Ltd; Siemens Healthineers AG

Market Segment Insights

The CT scan segment is projected to represent a large market share

Based on modality, the ovarian cancer diagnostics & therapeutics market is bifurcated into therapeutics and diagnosis. The diagnosis segment is further divided into biopsy, blood tests, ultrasound, pet, CT scan, and others. The CT scan is expected to represent a key share of the market during the forecast period. It creates detailed pictures or scan of body to see if the tumor is growing into nearby structures.

The epithelial ovarian tumors battery segment is expected to expand at a rapid pace

In terms of cancer types, the ovarian cancer diagnostics & therapeutics market is segmented into ovarian germ cell tumors, epithelial ovarian tumors, and others. The epithelial ovarian tumors segment is expected to represent a key share of the market in the coming years due to commonly spread to the lining and organs starting from pelvis and abdomen.

Ovarian Cancer Diagnostics & Therapeutics Market By Cancer Types

North America is anticipated to dominate the market

On the basis of regions, the ovarian cancer diagnostics & therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. Growth of the market is attributed to rising number of diagnostic centers in the region, ovarian cancer is the ninth most frequent cancer.

Ovarian Cancer Diagnostics & Therapeutics Market By Regions

Segments

Segments Covered in the Report
The global ovarian cancer diagnostics & therapeutics market has been segmented on the basis of

Modality
  • Therapeutics
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Hormonal Therapy
  • Others
  • Diagnosis
  • Biopsy
  • Blood Tests
  • Ultrasound
  • PET
  • CT scan
  • Others
 Cancer Types
  • Ovarian Germ Cell Tumors
  • Epithelial Ovarian Tumors
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Glaxosmithkline Plc.
  • Johnson and Johnson
  • Astrazeneca plc.
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG

Competitive Landscape

Key players competing in the ovarian cancer diagnostics & therapeutics market include GlaxoSmithKline Plc.; Johnson and Johnson; AstraZeneca plc.; F. Hoffmann-La Roche Ltd; and Siemens Healthineers AG.

Some of these players are using several market strategies such as acquisitions, merger, collaborations, partnerships, capacity expansion, and product launches to enhance their market shares and to generate revenue and rise their production line of the business in the coming years.

Ovarian Cancer Diagnostics & Therapeutics Market By Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ovarian Cancer Diagnostics & Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Ovarian Cancer Diagnostics & Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Ovarian Cancer Diagnostics & Therapeutics Market - Supply Chain
  4.5. Global Ovarian Cancer Diagnostics & Therapeutics Market Forecast
     4.5.1. Ovarian Cancer Diagnostics & Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Ovarian Cancer Diagnostics & Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Ovarian Cancer Diagnostics & Therapeutics Market Absolute $ Opportunity
5. Global Ovarian Cancer Diagnostics & Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Ovarian Cancer Diagnostics & Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Ovarian Cancer Diagnostics & Therapeutics Demand Share Forecast, 2019-2026
6. North America Ovarian Cancer Diagnostics & Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Ovarian Cancer Diagnostics & Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Ovarian Cancer Diagnostics & Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Ovarian Cancer Diagnostics & Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Ovarian Cancer Diagnostics & Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Ovarian Cancer Diagnostics & Therapeutics Demand Share Forecast, 2019-2026
8. Europe Ovarian Cancer Diagnostics & Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Ovarian Cancer Diagnostics & Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Ovarian Cancer Diagnostics & Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Ovarian Cancer Diagnostics & Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Ovarian Cancer Diagnostics & Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Ovarian Cancer Diagnostics & Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Ovarian Cancer Diagnostics & Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Ovarian Cancer Diagnostics & Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Ovarian Cancer Diagnostics & Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Ovarian Cancer Diagnostics & Therapeutics Market: Market Share Analysis
  11.2. Ovarian Cancer Diagnostics & Therapeutics Distributors and Customers
  11.3. Ovarian Cancer Diagnostics & Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Glaxosmithkline Plc. Johnson and Johnson Astrazeneca plc. F. Hoffmann-La Roche Ltd Siemens Healthineers AG
Segments Covered in the Report
The global ovarian cancer diagnostics & therapeutics market has been segmented on the basis of

Modality
  • Therapeutics
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Hormonal Therapy
  • Others
  • Diagnosis
  • Biopsy
  • Blood Tests
  • Ultrasound
  • PET
  • CT scan
  • Others
 Cancer Types
  • Ovarian Germ Cell Tumors
  • Epithelial Ovarian Tumors
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Glaxosmithkline Plc.
  • Johnson and Johnson
  • Astrazeneca plc.
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG

Key players competing in the ovarian cancer diagnostics & therapeutics market include GlaxoSmithKline Plc.; Johnson and Johnson; AstraZeneca plc.; F. Hoffmann-La Roche Ltd; and Siemens Healthineers AG.

Some of these players are using several market strategies such as acquisitions, merger, collaborations, partnerships, capacity expansion, and product launches to enhance their market shares and to generate revenue and rise their production line of the business in the coming years.

Ovarian Cancer Diagnostics & Therapeutics Market By Key Players

Buy Report